Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial
The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · 2666-2673
DOI: 10.1210/clinem/dgae867 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.12.2024. Verfasst von Vivian Szymczuk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Fibrous Dysplasia of Bone. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Dental and Craniofacial Research, National Institutes of Health, Amgen, Inc, National Institute of Dental and Craniofacial Research.
Abstract (Originalsprache)
Context
Fibrous dysplasia (FD) is a rare skeletal mosaic disease associated with fractures and disability. A phase 2 trial of the RANKL inhibitor denosumab (NCT03571191) reported profound reductions in lesion activity and increased lesional mineralization after 6 months of high-dose treatment. Denosumab was well tolerated; however, discontinuation was associated with severe hypercalcemia.
Objective
Investigate the safety and efficacy of moderate-dose denosumab (120 mg/3 months) compared to the standard high-dose regimen.
Setting
Clinical research center. Patients Adults with FD.
Interventions
Eight adults received high-dose denosumab for 6 months (120 mg/month with loading doses on weeks 2 and 3) followed by an 8-month posttreatment observation. The protocol was amended to restart moderate-dose denosumab (120 mg/3 months) if clinically indicated. Main Outcome Measures Bone turnover markers, 18F-sodium fluoride positron emission tomography/computed tomography (18F-NaF PET/CT), lesion biopsies.
Results
In 6 subjects who restarted moderate-dose treatment, changes in serum markers at the initial and final dose were comparable (procollagen type 1 N-terminal propeptide −82% and −91%, C-terminal telopeptide −86% and −86% for moderate- and high-dose, respectively). There was no difference in 18F-NaF PET/CT lesional activity or absolute change in avid lesion volume between moderate- and high-dose regimens. Sequential tissue histological analyses in 1 subject demonstrated progressive lesional mineralization and reduced cellularity with moderate-dose treatment. Bone turnover markers on moderate-dose treatment showed a sustained decline in 4 subjects; however, 2 severely affected subjects developed rebound between doses, with recurrent hypercalcemia in 1 subject.
Conclusion
Moderate-dose denosumab may provide clinical benefits comparable to the high-dose regimen in adults with FD while potentially lowering associated risks. However, discrepancies in the duration of efficacy are an important potential safety concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
- School of Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
- Biostatistics and Clinical Epidemiology, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19103, USA.
- Institute of Nuclear Medicine, Radiology and Imaging Sciences, Bethesda, MD 20892, USA.
ORCID-Profile: Vivian Szymczuk, Alison M Boyce
Förderung
- National Institute of Dental and Craniofacial Research, National Institutes of Health
- Amgen, Inc
- National Institute of Dental and Craniofacial Research
- National Institutes of Health
Zitieren
APA
Szymczuk, V., Elbashir, I. I., Ahmed, R., de Castro, L. F., Milligan, K., Li, X., Saboury, B., & Boyce, A. M. (2025). Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 110(9), 2666-2673. https://doi.org/10.1210/clinem/dgae867
Vancouver
Szymczuk V, Elbashir II, Ahmed R, de Castro LF, Milligan K, Li X, et al. Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):2666-2673. doi:10.1210/clinem/dgae867
BibTeX
@article{Szymczuk2025,
author = {Szymczuk, Vivian and Elbashir, Ibrahim I and Ahmed, Ramzy and de Castro, Luis F and Milligan, Kelly and Li, Xiaobai and Saboury, Babak and Boyce, Alison M},
title = {Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {9},
pages = {2666--2673},
doi = {10.1210/clinem/dgae867}
}
EUVIMED